BBIO — BRIDGEBIO PHARMA INC

Ownership history in Frazier Life Sciences Management, L.P.  ·  12 quarters on record

This page tracks every 13F SEC filing in which Frazier Life Sciences Management, L.P. reported a position in BRIDGEBIO PHARMA INC (BBIO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
7.28% (2025 Q4)
Avg. % of fund
4.74%
First filed
2023 Q1
Last filed
2025 Q4
Quarters held
12
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 3,545,557 -299,900 -7.8% 7.28% $271.2M $76.49
2025 Q3 ADDED 3,845,457 +45,000 +1.2% 5.98% $199.7M $51.94
2025 Q2 UNCHANGED 3,800,457 — 0% 6.56% $164.1M $43.18
2025 Q1 UNCHANGED 3,800,457 — 0% 6.00% $131.4M $34.57
8 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    BBIO price (monthly, adj. close)

Other funds also holding BBIO

As of 2025 Q4 — sorted by position size

Aisling Capital Management LP 3Y 7Y 81.29% Kohlberg Kravis Roberts & Co. L.P. 3Y 7Y 16.22% First Turn Management, LLC 5.2% BOONE CAPITAL MANAGEMENT LLC 3Y 4.44% Eagle Health Investments LP 3Y 4.36% Monashee Investment Management LLC 3Y 7Y 4.31% Cormorant Asset Management, LP 3Y 7Y 4.24% Atle Fund Management AB 3Y 7Y 3.45% Laurion Capital Management LP 3Y 7Y 3.28% FARALLON CAPITAL MANAGEMENT LLC 3Y 7Y 3.25%
← Back to Frazier Life Sciences Management, L.P. Holdings